Over the past few years, semaglutide medications such as Ozempic, Wegovy, and Rybelsus have transformed the treatment of type 2 diabetes and obesity. Their rapid adoption has reshaped treatment, sparked widespread public interest, and introduced new considerations for healthcare providers—including dentists.
In this CDA Oasis discussion, Dr. Aviv Ouanounou, a dental pharmacologist and Associate Professor at the University of Toronto Faculty of Dentistry, discusses his recent article Oral Health Considerations and Dental Management Guidelines for Semaglutide Medications, which was recently published in the Canadian Journal of Diabetes. Dr. Ouanounou outlines what we know so far about the impact of GLP-1 medications on oral health and offers guidance on how best to manage dental patients undergoing this therapy.
Dr. Ouanounou would like to thank his co-author, Ms. Karina Kofman, for her contribution to the study.
Helpful links:
Do you have a discussion topic or presentation you’d like to share with your colleagues on CDA Oasis or in CDA Essentials magazine? We'd love to hear from you! Topics can be related to the dental office setting, be clinical in nature, demonstrate social or community impact, and more!
Please send brief details to publications@cda-adc.ca